Published Studies Related to Sandostatin LAR Depot (Octreotide Long Acting)
Well-designed clinical trials related to Sandostatin LAR Depot (Octreotide Long Acting)
Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. [2008.10]
Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. [2007.09.03]
A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. [2007.07]
Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. [2007.06.21]
Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. [2007.01]
Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. [2006.12]
Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting Release Octreotide for Treatment of Graves' Ophthalmopathy. [2006.09.19]
A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. [2006.02]
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. [2005.10]
A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. [2005.09.13]
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. [2005.07]
Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. [2005.07]
Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. [2005.02]
Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. [2004.12]
The somatostatin analogue octreotide impairs sleep and decreases EEG sigma power in young male subjects. [2004.01]
A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. [2002.09]
A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. [2002.07]
Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1). [2002.03]
A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. [2002.01.15]
Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. [2002.01]
Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial. [2001.09]
Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. [2001.05]
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. [2000.11]
Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular treatment. [2000.09]
Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. [2000.09]
Octreotide in the prevention of pancreatic damage induced by endoscopic sphincterotomy. [2000.04.19]
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. [1999.02]
[Octreotide in the treatment of advanced pancreatic tumor. Preliminary study] [1998.12]
Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. [1998.11]
Dose-dependent effect of octreotide on insulin secretion after OGTT in obesity. [1998]
A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. [1997.02]
Treatment of migraine attacks with a long-acting somatostatin analogue (octreotide, SMS 201-995). [1997.02]
[Octreotide in the prevention of hyperamylasemia following ERCP (a controlled multicenter study)] [1996.10.20]
Efficacy of octreotide in diarrhoea due to Vibrio cholerae: a randomized, controlled trial. [1996.10]
Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. [1996.07]
A prospective, double-blind trial of somatostatin analog (octreotide) versus glucagon for the inhibition of small intestinal motility during endoscopic retrograde cholangiopancreatography. [1995.10]
Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. [1995.08]
Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. [1995.01.01]
Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: a double-blind randomized echo-Doppler study. [1995.01]
Controlled trial of different dosages of octreotide in the prevention of hyperamylasemia induced by endoscopic papillosphincterotomy. [1994.12]
Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial. [1994.11]
The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. [1994.11]
Octreotide administration, under particular temporal conditions, enhances the responses of growth hormone to growth hormone-releasing hormone in normal subjects. [1994.03]
Effects of the long-acting somatostatin analogue octreotide on abomasal function and plasma level of insulin and glucagon in sheep. [1994]
Sandostatin therapy of acute oesophageal variceal bleeding. [1993]
A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. [1992.11]
Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. [1992.11]
Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? [1992.08]
A prospective randomized controlled trial of sandostatin and vasopressin in the management of acute bleeding esophageal varices. [1992.06]
Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. [1992.03]
Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 201-995). [1992.02]
Role of octreotide in the prevention of postoperative complications following pancreatic resection. [1992.01]
Continuous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients with insulin-dependent (type 1) diabetes. [1991.07]
Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. [1990.12]
Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome. [1990.12]
Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy. [1989.06]
Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers. [1987]
Well-designed clinical trials possibly related to Sandostatin LAR Depot (Octreotide Long Acting)
Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. [2006.08]
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. [2005.07]
Role of somatostatin analogues in the management of enterocutaneous fistulae. [2004.04]
Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. [2004.03]
[A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer] [2001.10]
Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. [2000.12]
The use of long-acting somatostatin analogues in acromegaly. [2000.04]
The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. [1996.10]
Somatostatin pretreatment enhances growth hormone (GH) responsiveness to GH-releasing hormone: a potential new diagnostic approach to GH deficiency. [1996.07]
Intracolonic injection of glycerol: a model for abdominal pain in irritable bowel syndrome? [1996.02]
Effects of a long acting somatostatin analog on pituitary, adrenal, and testicular function during rest and acute exercise: unexpected stimulation of testosterone secretion. [1995.11]
Inhibition of omeprazole induced hypergastrinaemia by SMS 201-995, a long acting somatostatin analogue in man. [1993.09]
Pretreatment with somatostatin analog SMS 201-995 potentiates growth hormone (GH) responsiveness to GH-releasing factor in short children. [1993.09]
Somatostatin in acute bleeding oesophageal varices. Clinical evidence. [1992]
Control of dumping symptoms by somatostatin analogue in patients after gastric surgery. [1991.10]
The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography. [1991.01]
Effect of long-acting somatostatin analog (SMS 201-995) on high glomerular filtration rate in insulin dependent diabetic patients. [1990.07]
Long acting somatostatin analogue in dumping syndrome. [1989.12]
The long-acting somatostatin analogue SMS 201-995 causes malabsorption. [1989.12]
Intravenous and subcutaneous administration of a long-acting somatostatin analogue: effects on glucose metabolism and splanchnic haemodynamics in healthy subjects. [1989.04]
SMS 201-995 prevents postprandial blood pressure reduction in normotensive and hypertensive elderly subjects. [1988.12]
Other research related to Sandostatin LAR Depot (Octreotide Long Acting)
Established and potential therapeutic applications of octreotide in palliative care. [2008.10]
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. [2008.09.10]
Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. [2008.09]
Long-acting Octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader Willi syndrome. [2008.07.04]
Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. [2008.07]
Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. [2008.07]
Effects of octreotide on healing of mechanical ileus in rats. [2008.04]
A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. [2008.03]
Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. [2008.03]
Established and potential therapeutic applications of octreotide in palliative care. [2008.02.07]
Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. [2008.01]
Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report. [2008]
Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis. [2007.12]
Treatment of autonomic neuropathy, postural tachycardia and orthostatic syncope with octreotide LAR. [2007.12]
Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. [2007.11]
A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. [2007.10.17]
Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. [2007.10]
Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia. [2007.09.15]
Acromegaly caused by a growth hormone-releasing hormone secreting carcinoid tumour of the lung: the effect of octreotide treatment. [2007.07]
Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. [2007.06]
Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma. [2007.06]
Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide. [2007.06]
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. [2007.06]
|
